https://cdnimg.rg.ru/img/content/191/80/90/iStock-1183908006_d_850.jpg

the health Ministry explained that vincristine for all patients produce SMRC Oncology. N. N. Blokhin, the Israeli company “Teva” and Russian “Veropharm”. “Teva” has suspended its import to our country in March 2019, the supply will resume only after the decision on the registration of maximum ex-works price of the drug. “Veropharm” temporarily refused to release the cure, but again ready to start production until March 2021. To increase the volume of production of the drug instructed the state SMRC Oncology. N. N. Blokhin. Until the end of the year it’s supposed to produce 105 thousand packages of vincristine, a cancer research center (earlier the center produced 46 thousand packs per year). However, the Director of Fund “present life” Ekaterina Shergova doubt that he has enough for this capacity.

“According to our estimates, the stock-outs of the drug when you run out of stocks may occur at the end of this year,” said Shergova “RG”. Irregular supply of medicines in hospitals began in April, that’s when it began to contact the parents of sick children asking for help to find and purchase the drug.

“Vincristine is not the only pharmaceuticals that have been in the same situation,” – said the expert of the Russian society of clinical Oncology Nikolay Zhukov. Like the fate of other drugs that also are cheap, because appeared on the market a long time, and patent protection is over, and the range of applications they are limited. For example, vincristine requires only several thousands of patients. But for them this medicine is vital. Given that everything else in the country there is a practice of price fixing on medications, and production costs are rising, pharmaceutical companies produce these drugs at some point it becomes unprofitable.

Zhukov said that such a situation, with cheap drugs that required a limited number of patients, there and abroad. “To prevent this from happening, the manufacturer should be beneficial to deliver the drug,” he says.

According to him, of course, possible and the second option – creating a list of drugs that the government should provide. However, experts doubt its effectiveness: first, it will kill competition, and secondly, given the rate of development of pharmaceutical market, drugs outside the essential list getting longer.

Previous articleNot absorbed with milk
Next articleAbbot Sergius demanded that Putin resign
Jennifer Alvarez is an investigative journalist and is a correspondent for European Union. She is based in Zurich in Switzerland and her field of work include covering human rights violations which take place in the various countries in and outside Europe. She also reports about the political situation in European Union. She has worked with some reputed companies in Europe and is currently contributing to USA News as a freelance journalist. As someone who has a Masters’ degree in Human Rights she also delivers lectures on Intercultural Management to students of Human Rights. She is also an authority on the Arab world politics and their diversity.